Regeneron Pharmaceuticals announces results from phase III trial of REGEN-COV (casirivimab with imdevimab) antibody cocktail in recently infected asymptomatic COVID-19 patients

Company reports that treatment decreased overall risk of patients progressing to symptomatic COVID-19 by 31%, which was the trial's primary endpoint. It also decreased overall risk of progression by 76% after the third day, as well as duration of symptoms and viral levels.

SPS commentary:

Regeneron also reported results from second trial of REGEN-COV evaluating its ability to decrease the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals, which decreased the risk of symptomatic infections by 81% in people who were not infected when they began the trial. On average, people receiving the antibody therapy who had symptomatic infection had resolution of their symptoms in one week, compared to three weeks with placebo.

REGEN-COV is still being studied in clinical trials in multiple settings. These include for prevention of COVID-19 in households contacts of infected people; in non-hospitalised and certain hospitalised patients, including the open-label RECOVERY trial of hospitalised patients being run in the U.K.

Biospace Inc.